Table 1.
Patient and lesion characteristics.
| Cohort 1 1 mg BLZ-100 (N = 3) | Cohort 2 3 mg BLZ-100 (N = 3) | Cohort 3 6 mg BLZ-100 (N = 6) | Cohort 4 12 mg BLZ-100 (N = 6) | Cohort 5 18 mg BLZ-100 (N = 3) | All Subjects (N = 21) | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| Median (range): | 53.0 (48, 67) | 67.0 (56, 72) | 56.5 (45, 78) | 53.5 (44, 68) | 60.0 (53, 80) | 58.0 (44, 80) |
| Gender, n (%) | ||||||
| Male: | 2 (66.7) | 2 (66.7) | 3 (50.0) | 2 (33.3) | 1 (33.3) | 10 (47.6) |
| Female: | 1 (33.3) | 1 (33.3) | 3 (50.0) | 4 (66.7) | 2 (66.7) | 11 (52.4) |
| Weight (kg) | ||||||
| Median (range): | 68.4 (62.9, 150.0) | 99.5 (88.6, 102.9) | 80.0 (55.9, 133.4) | 84.4 (64.5, 162.2) | 64.5 (51.1, 74.9) | 83.5 (51.1, 162.2) |
| Cohort 1 (N = 6 lesions) | Cohort 2 (N = 3 lesions) | Cohort 3 (N = 9 lesions) | Cohort 4 (N = 6 lesions) | Cohort 5 (N = 5 lesions) | All Lesions (N = 29) | |
| Final skin cancer diagnosis1, n (%) | ||||||
| BCC: | 2 (33.3) | 2 (66.6) | 4 (44.4) | 0 | 5 (100) | 13 (44.8) |
| SCC: | 2 (33.3) | 0 | 0 | 0 | 0 | 2 (6.9) |
| Melanoma: | 0 | 0 | 3 (33.3) | 1 (16.7) | 0 | 4 (13.8) |
| Other2: | 2 (33.3) | 1 (33.3) | 2 (22.2) | 5 (83.3) | 0 | 10 (34.5) |
max = maximum; min = minimum; BCC = basal cell carcinoma; SCC = squamous cell carcinoma.
1Final diagnoses were determined on Day 3 post-excision by histopathology. A total of 29 lesions from 21 patients were analyzed.
2Unidentified or non-cancerous.